The evidence on peptides — delivered weekly. Subscribe free →

IGF-1 (Native)

low risk

Also: Insulin-like Growth Factor 1 · Somatomedin C · IGF1

Strong Evidence Research Only

Reference entry for native IGF-1 — the primary mediator of growth hormone's anabolic and tissue-repair effects. Produced primarily by the liver in response to GH. Half-life ~15 hours when bound to IGFBPs. The target axis for multiple peptide classes (GHRPs, GHRH analogs, IGF-1 analogs).

Molecular Weight
7649.1 Da
Formula
C331H512N94O101S7
Common Dosing
Not typically used as native injection; recombinant mecasermin (Increlex) is FDA-approved for growth failure
Category
research
Last Reviewed
2025-01-15

Reported Benefits

Growth and tissue repair

Strong Evidence 450 studies

Well-characterized mediator of GH effects. Mecasermin (recombinant IGF-1) FDA-approved for growth failure.

Mechanism of Action

Binds IGF-1R (type 1 IGF receptor); activates PI3K-Akt-mTOR and MAPK pathways; mediates GH effects on muscle, bone, and organ growth; central to tissue repair signaling.

Key Clinical Studies

Ranke & Elmlinger (1997)

Review · Review

PubMed →

Comprehensive characterization of IGF-1 receptor pharmacology and clinical effects

Mecasermin: The Approved IGF-1 Drug

Recombinant IGF-1 (mecasermin/Increlex) is FDA-approved for short stature due to primary IGF-1 deficiency. This approval establishes the pharmacological basis for IGF-1 axis manipulation as a legitimate therapeutic approach.

Long R3 IGF-1 and other analogs are engineered to improve on native IGF-1’s pharmacokinetics.

✦ Sponsored

Stop Guessing About Your Health. Start Optimizing It.

Advanced diagnostics and licensed medical providers delivering personalized longevity care to uncover root causes, optimize health, and track progress virtually or in person.

Learn More →
Nava Health

Regulatory Status

Research Only

Recombinant IGF-1 (Increlex) FDA approved for IGF-1 deficiency

Safety Profile

Side Effects

  • Hypoglycemia (clinical doses)
  • Jaw/soft tissue growth (acromegalic effects)
  • Carcinogenic risk (IGF-1R is oncogenic)

Contraindications

  • Active malignancy
  • Diabetic retinopathy
  • Closed epiphyses with growth intent

Drug Interactions

  • Insulin (severe hypoglycemia risk)

Primary Uses

Educational referenceGH axis physiologyGrowthTissue repair

Planning a protocol?

Use the AI Stack Builder to generate a phased schedule, compatibility analysis, and monitoring checklist.

Weekly Briefing

Regulatory updates + new study breakdowns.

For Practitioners

Do you prescribe IGF-1 (Native)?

Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.

Get Listed →
Disclaimer: This information is for educational and research purposes only. Not medical advice. Consult a qualified healthcare provider before using any compound.